Latest Insights - page 69 | BiopharmaTrend

Revolutionizing Clinical Trials: How AI and Automation Reduced Study Build Time from Months to Days

AI Integration Advances Lung Fibrosis Patient Stratification in Clinical Trials

In a collaborative effort between Brainomix, an AI-powered medical technology company, and AstraZeneca, a new study demonstrates significant advancements in the identification and stratification of patients with idiopathic pulmonary fibrosis …

Continue ›››

NVIDIA Introduces New Software Tools for Biopharma AI Applications

NVIDIA's CEO, Jensen Huang, recently outlined the company's expanded focus on software solutions designed to facilitate the adoption of artificial intelligence (AI) in the biopharmaceutical sector, beyond its well-established position …

Continue ›››

Denmark Collaborates with NVIDIA to Establish AI Innovation Centre Featuring Advanced Supercomputer

Denmark is set to create a national AI innovation centre in collaboration with NVIDIA, aiming to host one of the most powerful AI supercomputers globally. This initiative is driven by …

Continue ›››

AI Becomes a Drop-in Replacement for Docking

Notable Trends and Companies to Follow in Neuroscience

Historically, the approval rate for medicines treating central nervous system (CNS) disorders was low. By 2022, the success rate for CNS assets from phase 1 through to regulatory submission was only …

Continue ›››

Basecamp Research Introduces BaseFold, Enhancing Accuracy in Protein Structure Prediction

Basecamp Research announced the development of BaseFold, a new deep learning model designed to predict the 3D structures of large, complex proteins with unprecedented accuracy. This model represents a significant …

Continue ›››

11 Biopharma Trends to Watch in 2024

2023 has marked a remarkable year of technological advancements in drug discovery and biotechnology. Ironically, the elation from a kaleidoscope of technological and scientific advances is in stark contrast with …

Continue ›››

Recursion Expands Its Presence with a New London Office and Bolsters Scientific Advisory Team

Recursion (NASDAQ: RXRX), a clinical-stage TechBio company, has unveiled plans to establish a new office in London's King’s Cross area, aiming to tap into the European pool of TechBio talent. …

Continue ›››

A Leap into the Future: FDA Greenlights Transformative Advances in Robotic Surgery

Recently, the robotic surgery industry was marked by two important announcements. On February 22, 2024, FDA granted 510(k) clearance to Zimmer’s ROSA shoulder-replacement robot.

Continue ›››

Elsevier and Iktos Collaborate to Boost Drug Discovery with AI-Enhanced Chemistry Database

Elsevier, a global provider of information and analytics in science and health with 140 years of history, has entered into a strategic partnership with Iktos, a French artificial intelligence (AI) …

Continue ›››

Towards 100 Billion Data Points for Advanced Drug Discovery and Treatment Combinations

Lantern Pharma, a NASDAQ-listed company specializing in AI-driven cancer drug discovery and development, has announced a milestone with its artificial intelligence platform for precision medicine, RADR®, aiming at a greater focus on data …

Continue ›››